Katharine A. Phillips, M.D.
Name, Degree: Katharine A. Phillips, M.D.
Role(s) in Task Force and Work Group: Member, DSM-V Task Force and Chair, Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group
Institutional Affiliation(s): Butler Hospital and the Alpert Medical School of Brown University
City, State: Providence, RI
Biographical Sketch:
Katharine A. Phillips, M.D.
Chair, Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group
Member, DSM-V Task Force
Professor of Psychiatry and Human Behavior, Butler Hospital and the Alpert Medical School of Brown University
Providence, RI
Dr. Katharine Phillips is Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. Dr. Phillips received her bachelor’s degree from Dartmouth College and her medical degree from Dartmouth Medical School. She completed her internship at Dartmouth Medical School and her residency at McLean Hospital/Harvard Medical School.
Much of Dr. Phillips’ career has focused on clinical research on body dysmorphic disorder as well as obsessive compulsive disorder, other anxiety disorders, and personality disorders. Dr. Phillips has received numerous honors and awards for her research and other academic contributions, including a Special Presidential Commendation from the American Psychiatric Association for her research accomplishments. She has been a member and chair of the National Institute of Mental Health’s Interventions Research Review Committee (Initial Review Group). Dr. Phillips is Secretary of the Board of Directors and Deputy Editor (Books Division) of American Psychiatric Publishing, and she is a member of a number of other editorial boards. Dr. Phillips is also a member of the American College of Neuropsychopharmacology and the American College of Psychiatrists.
Dr. Phillips chaired the committee that produced the gender white paper for the Research Agenda for DSM-V and participated in the DSM-V research planning conference on the obsessive compulsive behavior spectrum. She has been a member and chair of the American Psychiatric Association’s Committee on Psychiatric Diagnosis and Assessment and a member of the Council on Research. She co-edited the book Advancing DSM: Dilemmas in Psychiatric Diagnosis.
Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)
|
Non-Profit and Advocacy Organizations |
Year(s) |
Role |
|
Association for Research on Personality Disorders |
2003-2006 |
Board of Directors |
|
American Psychiatric Publishing, Inc |
2006-2008 |
Board of Directors and Secretary |
| American Psychiatric Publishing, Inc |
2008 |
President, Board of Directors |
The two tables below represent Dr. Phillips’ disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.
Dr. Phillips has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, her aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.
|
KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options |
6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify) |
Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
UCB Pharma |
2003 |
1 and 10 (travel expenses) |
|
Forest Laboratories |
2003 |
1 and 10 (travel expenses) |
|
Jazz Pharmaceuticals |
2005 |
1 |
|
Eli Lilly and Company |
2003 |
3 |
|
Forest Laboratories |
2003, 2004, 2005, 2006 |
3 |
|
UCB Pharma |
2004, 2005, 2006 |
3 |
|
Association Francais des Troubles Anxieux and Lundbeck Pharmaceuticals |
2003 |
4 and 10 (travel expenses) |
|
Pfizer |
2003 |
4 and 10 (travel expenses) |
|
Forest Laboratories |
2004 |
4 and 10 (travel expenses) |